Ester insulin

• US 8,618,049 B2
• Filed: 09/07/2010
• Issued: 12/31/2013
• Est. Priority Date: 09/08/2009
• Status: Active Grant

• Current Assignee: Stephen B.H. Kent, Youhei Soma
• Original Assignee: Stephen B.H. Kent, Youhei Soma
• Inventors: Kent, Stephen B. H., Soma, Youhei
• Primary Examiner(s): Tsang, Cecilia J
• Assistant Examiner(s): Miknis, Zachary J
• Application Number:
  US13/394,646
• Publication Number:
  US 20120220522A1
• Time in Patent Office: 1,211 Days
• Field of Search: None
• US Class Current: 514/6.2
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

Compositions and methods related to ester insulin or derivatives thereof are provided. The compositions include Glu^A4-Thr^B30 ester insulin, in which side chains of Glu^A4 and Thr^B30 of native human insulin or an insulin analogue such as insulin lispro are covalently linked via a single ester bond. The ester insulin is efficiently folded, forming the desired disulfides. The Thr^B30-Glu^A4 ester bond can be cleaved in vitro or in vivo to give the desired folded insulin with full biological activity. The ester insulin is readily prepared by total chemical synthesis, and amendable to cost-effective, large scale manufacturing. Also provided are pharmaceutical compositions and kits for use in practicing the subject methods. Also provided are methods of using the subject compositions and kits in the treatment of a variety of different disease conditions, particularly glucose metabolic disorders such as diabetes and obesity.

Claims

1. A composition comprising an ester insulin or derivative thereof, wherein the ester insulin comprises A-chain and B-chain peptides of an insulin active agent, the A-chain and B-chain peptides comprising amino acids corresponding in position to human insulin A-chain glutamate 4 (Glu^A4) and B-chain threonine 30 (Thr^B30), the amino acids covalently linked through their side chains by an ester bond.

2. The composition of claim 1, wherein the ester insulin is ester insulin lispro.

3. The composition of claim 1, wherein the insulin active agent is insulin lispro.

4. The composition of claim 1, wherein the ester insulin or derivative thereof is the folded, disulfide form.

5. The composition of claim 1, wherein the composition is comprised as a pharmaceutical formulation.

9. A kit comprising a composition according to claim 1 or claim 8 and a delivery device.

10. A composition according to claim 1 or claim 8, comprised as a subcutaneous slow release depot formulation.

6. A method of producing insulin, the method comprising

(i) providing ester insulin, the ester insulin comprising A-chain and B-chain peptides of an insulin active agent, the A-chain and B-chain peptides comprising amino acids corresponding in position to human insulin A-chain glutamate 4 (Glu^A4) and B-chain threonine 30 (Thr^B30), the amino acids covalently linked through their side chains by an ester bond;

and

(ii) cleaving the ester bond under conditions that form the insulin active agent.

7. A method of administering to a host in need thereof an effective amount of an ester insulin or derivative thereof, the method comprising administer to the host an effective amount of an ester insulin or derivative thereof effective to induce a reduction in blood glucose levels.

8. A composition comprising a compound of the formula: